Skip to main content
Premium Trial:

Request an Annual Quote

Crossing Their Fingers

Human Genome Sciences plans to release late-stage clinical data on Benlysta, its experimental drug for lupus, on Monday, reports Dow Jones Newswires. The story adds that lupus is "a notoriously hard-to-treat autoimmune disease that hasn't seen a new therapy in decades." Human Genome Sciences partnered with GlaxoSmithKline and worked closely with FDA to design its phase III trial after the phase II trial failed. The article says that if this first trial fails — Barclays analyst Jim Birchenough estimates an 85 percent chance of failure — the company's stock will likely drop to about $1; but if it meets its endpoints, the stock could reach higher than $10.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.